Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Heparin Market

U.S. Heparin Market Share

Report ID: GMI4868
Published Date: Nov 2020
Report Format: PDF

Download Free Sample

U.S. Heparin Market Share

Notable players operating in the U.S. heparin market include:

Pfizer
Amphastar Pharmaceutical
Sanofi
Shenzhen Hepalink
Fresenius Kabi
Nanjing King-Friend Biochemical Pharmaceutical.

Product launches & approvals, partnerships and geographical expansions are the most adopted business strategies to sustain market competition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Driven by a rising patient pool suffering from chronic illness coupled with increasing demand for anticoagulant products, the U.S. industry size of heparin surpassed USD 623 million in 2019 and is set to expand at more than 7.2% CAGR through 2026.

The low molecular weight heparin segment revenue in the U.S. was over USD 535.4 million in 2019 and is poised to grow substantially owing to its distinct biochemical and pharmacological properties.

The venous thromboembolism segment accounted for USD 328 million in 2019 and is likely to grow at a 6.8% rate through 2026 favoured by the rising number of patients requiring heparin for treatment of venous thromboembolism.

The hospital pharmacy segment held a market share of 54.3% in 2019, and the rising preference of patients towards hospitals due to ease of availability of medicines will boost the market growth.